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Abstract
Progressive multifocal leukoencephalopathy (PML) induced by JC virus (JCV) is a risk for natalizumab-treated multiple
sclerosis (MS) patients. Here we characterize the JCV-specific T cell responses in healthy donors and natalizumab-treated MS
patients to reveal functional differences that may account for the development of natalizumab-associated PML. CD4 and
CD8 T cell responses specific for all JCV proteins were readily identified in MS patients and healthy volunteers. The
magnitude and quality of responses to JCV and cytomegalovirus (CMV) did not change from baseline through several
months of natalizumab therapy. However, the frequency of T cells producing IL-10 upon mitogenic stimulation transiently
increased after the first dose. In addition, MS patients with natalizumab-associated PML were distinguished from all other
subjects in that they either had no detectable JCV-specific T cell response or had JCV-specific CD4 T cell responses uniquely
dominated by IL-10 production. Additionally, IL-10 levels were higher in the CSF of individuals with recently diagnosed PML.
Thus, natalizumab-treated MS patients with PML have absent or aberrant JCV-specific T cell responses compared with non-
PML patients, and changes in T cell-mediated control of JCV replication may be a risk factor for developing PML. Our data
suggest further approaches to improved monitoring, treatment and prevention of PML in natalizumab-treated patients.
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Introduction
Progressive Multifocal Leukoencephalopathy (PML) is a demy-
elinating disease of the central nervous system caused by JC virus
(JCV) [1]. PML occurs most often in the setting of immunode-
ficiency, such as AIDS, leukemia, organ transplantation and
idiopathic CD4 lymphopenia. However, cases of PML have
recently been reported after immunotherapy with monoclonal
antibodies, including approximately 260 cases in MS patients
treated with natalizumab (Tysabri) as of July 30, 2012. The risk of
PML increases with the number of natalizumab doses adminis-
tered with highest incidence after 24 [2–4]. The 2.1/1000 overall
risk of PML [2] is a major consideration in the decision to treat
with natalizumab. The mechanism underlying JCV reactivation in
natalizumab-treated individuals with MS is actively being inves-
tigated, but may involve both reduced immune surveillance of the
central nervous system due to attenuated extravasation of
leukocytes out of the bloodstream and into tissues [5–7], and also
latent viral infection in CD34+ cells that migrate from the bone
marrow to the peripheral circulation [8]. In this context,
characterization of the effects of natalizumab on T cell immune
control of JCV replication might shed light on the host and viral
factors that determine the risk for the development of PML.
Previous studies have measured CD4 and CD8 T cell responses
to JCV in individuals with PML who had not received
natalizumab therapy [9–14]. CD8 T cell responses to particular
JCV epitopes were found to be associated with longer survival
times after early PML in HIV-positive subjects [15], and a recent
study showed that CD4 and CD8 T cell responses to JCV were
more likely to be detected in PML survivors than in PML
progressors [16]. Most studies have focused solely on the
magnitude of JCV-specific T cell responses but the quality of the
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response also may be important [17]. In one study, HIV-related
PML was associated with a unique increase in JCV-specific
interleukin 10 (IL-10) production by bulk cultures of peripheral
blood mononuclear cells (PBMC), compared with non-HIV PML
samples [18]. Little is known about the quality of the JCV-specific
response in natalizumab-treated individuals. It has been reported
that after natalizumab treatment, the levels of mRNA for the
cytokines interferon gamma (IFNc) and IL-10 change, with IFNc
levels increasing in PBMC and decreasing in CSF cells and IL-10
levels increasing in CSF cells [19]. However, as these levels were
measured in bulk cultures from each compartment, it is not
possible to determine whether this finding simply reflects the
altered frequencies of different cell types in the blood and CSF that
are known to occur with treatment [7,20–22].
Two recent studies yielded disparate results when examining
longitudinal T cell responses to JCV in individuals with MS after
natalizumab treatment [23,24]. Notably, these studies measured
JCV-specific T cell responses directed against the VP1 protein by
interferon gamma production. We hypothesized that immune
control of JCV viremia in natalizumab-treated individuals might
depend on T cells directed at other portions of the virus and/or on
the range of the cytokines produced. To investigate the JCV-
specific T cell response in greater depth, we performed a detailed
characterization of the functional T cell response to the entire JC
virus proteome longitudinally in individuals initiating treatment
with natalizumab, and in individuals who had developed PML
after treatment with natalizumab.
Results
Detection of JCV-specific T cell responses
We characterized the T cell immune response to JCV in eight
patients with MS initiating natalizumab and ten healthy volun-
teers. As T cell responses have not been described to JCV proteins
other than VP1, we sought to determine whether either CD4 or
CD8 T cells were directed against the other portions of the virus.
We stimulated PBMC with 5 pools of peptides covering the entire
JCV proteome: large T antigen, small t antigen, VP1, VP2 and
agnoprotein. The peptides were 15mers overlapping by 11 amino
acids to optimize coverage of both CD4 and CD8 T cell epitopes,
and included additional peptides to cover JCV sequence variants
identified in the literature (as described in the materials andmethods).
Responses were measured by intracellular cytokine staining (ICS)
and polychromatic flow cytometry for cytokines associated with
effective control of viral infections: IFNc, tumor necrosis factor (TNF)
and interleukin 2 (IL-2), and for a cytokine associated with poor
control of viral infections [25–27], interleukin 10 (IL-10).
Both CD4 and CD8 memory T cell responses were readily
measured ex vivo from cryopreserved PBMC samples. Responses
were observed in all MS patients that variously targeted each of
the JCV proteins: large T antigen, small t antigen, VP1, VP2 and
agnoprotein (Figure 1). Notably, different viral proteins were
immunodominant in different individuals and most individuals
targeted more than one protein (Figure 1). Both CD4 and CD8 T
cells specific for JCV were observed in most subjects (Figure 1).
None of the responding T cells produced IL-10, but each
produced one or more of the other three cytokines, with a
significant fraction expressing two or three cytokines (Figure 1,
Figure 2A and data not shown). The specificity, magnitude and
functional profile of these responses varied among individuals.
Similar JCV-specific T cell responses were observed in all ten
healthy subjects (Figure S1).
Longitudinal antiviral immune responses in natalizumab-
treated individuals
To determine the impact of natalizumab after short-term
treatment, when risk of PML is low, we compared T cell responses
to JCV and cytomegalovirus (CMV) before and after the initiation
of natalizumab. The eight individuals with MS were examined at
baseline (month 0) before natalizumab therapy, one month after
the first infusion of natalizumab (month 1), and at the latest
timepoint available (after 3–7 monthly infusions).
The total CD4 and CD8 T cell responses to JCV, calculated as the
sum of the memory response to each of the five JCV peptide pools,
did not change significantly at different timepoints (Figure 2A).
There was also no significant difference in the magnitude of the
responses to each individual peptide pool (data not shown). The
functional profile of the CD4 and CD8 T cell responses to JCV,
defined by production of a combination of IFNc, TNF and IL-2, did
not vary significantly over time (Figure 2A). Although the relative
sizes of the slices of the pie charts representing different combinations
of cytokines produced by the T cells varied across timepoints, these
apparent differences were not statistically significant as determined
by the chi squared and permutation tests which were used to
calculate P values [28]. We therefore observed no change in the
magnitude, quality, or targeting of the JCV-specific immune
response early after initiation of natalizumab treatment.
CMV was chosen as a control antigen for JCV because it is a
prevalent DNA virus that, like JCV, is neurotropic and establishes
latent infection. The CMV pp65-specific CD4 and CD8 memory
T cell responses did not change in magnitude or functional profile
between the three timepoints (Figure 2B). None of the T cells
directed against JCV or CMV produced IL-10 at any timepoint.
These findings suggest that short-term natalizumab therapy does
not alter these antiviral immune responses.
Cellular immune response to mitogenic stimulation in
natalizumab-treated individuals
To gauge the impact of natalizumab on the overall memory T
cell response to stimulation we measured cytokine production after
Author Summary
Progressive multifocal leukoencephalopathy (PML) is a
complication of treatment with natalizumab in patients
with multiple sclerosis (MS) and Crohn’s disease. PML
results from a failure of the immune system to control
replication of JC virus (JCV) in the brain. We studied the T
cell responses of 8 patients with MS who were starting
treatment with natalizumab, 10 healthy volunteers, and 4
patients with natalizumab-associated PML. The magnitude
and quality of JCV-specific immune responses remained
unchanged after starting natalizumab. However, applying
the same methods and antigens, we found that immune
responses in the individuals who developed PML differed
from those in the MS patients and healthy volunteers. In
the four patients with PML from whom the laboratory had
identified JCV DNA in the cerebrospinal fluid (CSF), two
had no measurable T cell response to JCV and two had T
cells that produced IL-10, an anti-inflammatory mediator.
Furthermore, we studied the CSF of 10 patients with
natalizumab-associated PML and 10 patients on natalizu-
mab who had similar symptoms but did not have PML. We
found that IL-10 was detectable in the CSF of half of the
individuals with PML but none of the control group. These
findings shed light on the mechanisms that lead to PML in
a subset of patients treated with natalizumab and have
implications for therapeutic and preventative measures.
JCV T Cell Responses during Natalizumab Treatment
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stimulation with the mitogen SEB. No difference was observed in
the magnitude or profile of IFNc, TNF and IL-2 produced at the
different time points in response to SEB stimulation (data not
shown). We also measured IL-10 production because this
regulatory cytokine is associated with poor control of persistent
viral infections [25–27]. Upon mitogenic stimulation with SEB, a
small number of CD4 T cells produced IL-10. The frequency of
these cells increased after one dose of natalizumab, although this
effect was not sustained at later timepoints (Figure 3A). This
increase in the frequency of IL-10-producing memory CD4 T cells
is unlikely to result from a change in the frequency of the parent
population (total memory CD4 T cells) as the frequency of these
Figure 1. T cell responses to JC virus target each viral protein. PBMC from individuals with MS treated with natalalizumab who did not have
PML were stimulated with JCV peptide pools or costimulatory molecules alone (negative control) for 6 hours. Panel A shows memory CD4 T cells
from 3 samples; Panel C shows memory CD8 T cells from 3 samples. The fluorescence intensity of IFNc and TNF are shown on the X and Y-axes,
respectively. Panels B and D show baseline pre-treatment responses from all eight longitudinal subjects with MS, with the background-subtracted
magnitude of the response to each JCV protein depicted by colored bars. Responses were measured by production of any combination of IFNc, TNF
and IL-2, using Boolean gates and then background subtracting from each Boolean population.
doi:10.1371/journal.ppat.1003014.g001
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cells did not change across timepoints (data not shown). The
increased frequency of T cells that produce IL-10 after one dose of
natalizumab may indicate its potential to skew the functional
profiles of T cells.
In order to determine whether MS patients with natalizumab-
associated PML had similar T cell responses, we also examined the
response to mitogenic stimulation in T cells from four patients
whose CSF samples were previously tested in our laboratory for
JCV DNA. One of these patients, PML-4, was one of the first cases
diagnosed in 2005, who was followed for more than 5 years and
never cleared JCV from the brain [29]. Importantly, in three out
of the four subjects (PML-1, PML-3 and PML-4), a high frequency
of CD4 T cells produced IL-10 in response to mitogenic
stimulation with SEB, despite the discontinuation of natalizumab
in these individuals (Figure 3B). T cells from subject PML-2 did
not produce IL-10 in response to JCV, CMV or SEB stimulation
and this finding was confirmed in a second sample from PML-2
(data not shown). The observation that the frequency of IL-10
producing memory CD4 T cells was high in subjects with
natalizumab-associated PML raises the intriguing possibility that
the transient increase in these cells after treatment initiation might
indicate a potential role for natalizumab in skewing the immune
response toward a cytokine associated with PML.
Antiviral immune responses in individuals with
natalizumab-associated PML
Approximately 2.1/1000 MS patients treated with natalizumab
develop PML [2]. We hypothesized that such individuals might
have an aberrant T cell response to JCV. Given our findings that
Figure 2. Magnitude and functional profile of JCV and CMV-specific T cells do not change upon treatment. PBMC from individuals with
MS treated with natalalizumab who did not have PML were stimulated with JCV peptide pools, CMV pp65 peptide pool or costimulatory molecules
alone (negative control) for 6 hours. A response was considered positive if the frequency of memory T cells producing IFNc, TNF or IL-2 was higher in
the peptide-stimulated cells than in those stimulated with costimulatory molecules alone. Response size was calculated by measuring the frequency
of cells producing each Boolean combination of cytokines, and subtracting the frequency of these cells in the negative control. Summing the
background-subtracted Boolean subsets gave the total frequency of cytokine-producing memory T cells specific for the peptide pool. The total
response to JCV (Panel A) was calculated by summing the frequency of cells specific for each of the 5 JCV peptide pools. The functional profile of the
response is shown in the pie charts above, with the blue slice representing the proportion of responding cells that produce all 3 cytokines, the red
slices representing the proportion of cells that produce a combination of 2 cytokines, and the green slices representing the proportion of cells that
produce only 1 cytokine. Panel B shows the frequency of CD4 (left) and CD8 (right) memory T cells responding to the CMV pp65 peptide pool.
doi:10.1371/journal.ppat.1003014.g002
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JCV-specific T cells may target many of the JCV antigens and are
varied in functional profile among individuals, we sought to
identify whether there were differences in the antiviral immune
responses of individuals who developed PML after treatment with
natalizumab. We therefore characterized T cell responses in four
individuals with natalizumab-associated PML by measuring JCV-
specific production of IFNc, TNF, IL-2 and IL-10.
In two subjects, PML-1 and PML-2, no JCV-specific CD4 or
CD8 T cell responses were observed that were significantly
above background (Figure 4A). These were the only subjects in
whom no JCV-specific T cell responses were observed, as all the
MS patients and healthy volunteers had detectable responses.
The sample from PML-1 was taken 2 weeks after diagnosis with
PML, and the sample from PML-2 was taken 2 months after
diagnosis. Both subjects were still being followed 2 years after
diagnosis.
In PML-3 and PML-4, the JCV-specific T cell response had a
markedly different functional profile than was observed in any of
the non-PML or healthy subjects. These subjects, who were
diagnosed with PML 4 months and 5 years prior to sampling,
respectively, had JCV-specific CD4 T cells that produced IL-10
(Figure 4B). The specificity of the IL-10 response for PML-4 was
confirmed by double staining with the same antibody conjugated
to two different fluorophores (Figure S2). The antigen specificity
of the subjects’ responses differed. In subject PML-3, 1.5%
of the CD4 memory T cells produced IL-10 and were specific for
the small t antigen (Figure 4A, grey bar), while the sum of the
IFNc responses to all of the JCV peptide pools was 0.10%
(Figure 4A, red bar). The total IFNc-producing memory CD8 T
cell response was 0.26%. This subject died 1 month after
sampling. In subject PML-4, 0.34% of the CD4 memory T cells
produced IL-10 and were specific for VP1, while the sum of the
IFNc responses to all of the JCV peptide pools was 0.12% of
CD4 memory cells. The total IFNc-producing CD8 memory T
cell response was 0.44%. Subject PML-4 died 1 year after
sampling. Importantly, these were the only IL-10-producing
virus-specific T cell responses we observed among all the subjects
examined in this study. Thus, in contrast to non-PML MS
patients or healthy volunteers, individuals who developed PML
had JCV-specific T cell responses that were either uniquely
dominated by IL-10 producing cells or were undetectable.
CSF cytokines in natalizumab-associated PML
As JCV-specific T cells in the blood of the four individuals with
PML were either absent or of unusual functionality, we next
examined the cytokine profile within CSF samples from 10
individuals with natalizumab-associated PML, including subjects
PML 1–4, at the time of initial diagnosis. In addition, a second
CSF sample from a later time point was available for 8 of these
subjects. The samples were tested for the presence of 27 cytokines
and other markers and were compared to diagnostic CSF samples
from 10 individuals who had suspected natalizumab-associated
PML which was subsequently ruled out by a negative PCR for
JCV. Twelve of the molecules were undetectable in the vast
majority of CSF samples, including IL-1b, IL-2, IL-4, IL-12p70,
IL-17, Eotaxin, FGF basic, GM-CSF, IFNc, MIP1a, RANTES,
and TNF. An additional 12 molecules, IL-1ra, IL-6, IL-7, IL-8,
IL-9, IL-13, G-CSF, IP-10, MCP-1, PDGF-b, MIP1b and VEGF,
were measured in the CSF samples but did not vary in PML and
non-PML samples. Although the assay was not sensitive enough
for accurate quantification of low levels of IL-10, it could readily
distinguish whether IL-10 was detectable above background.
Thus, we found that 50% of the PML CSF samples had detectable
IL-10, while none of the non-PML samples had detectable IL-10
(P=0.0325, Figure 5A). Similarly, for IL-5, 60% of the PML
samples had IL-5 levels above the limit of quantification, while
none of the non-PML samples had IL-5 levels that could be
quantitatively measured (P=0.0108, Figure 5A). Thus, higher
levels of IL-10 and IL-5 can be detected in the CSF of individuals
with natalizumab-associated PML. Finally, in the samples from
early in PML disease, levels of IL-15 in the CSF were significantly
higher than in later samples from the same subjects (P=0.02), or
in the samples from non-PML subjects (P=0.004). These results
reveal a PML-specific CSF cytokine profile that may reflect the
altered cytokine profile we observed in JCV-specific T cells in the
blood.
Discussion
The factors that lead to the development of PML in individuals
treated with natalizumab need to be investigated in more detail,
particularly immune responses to the virus. Consequently, we
investigated the T cell immune response to the entire JC virus
Figure 3. Transient increase in IL-10-producing cells after natalizumab initiation and high frequency in individuals with PML. PBMC
from all studied MS patients were stimulated with SEB. Background-subtracted frequency of memory CD4 T cells producing IL-10 is shown. P value
from month 0 to month 1 is the result of Wilcoxon matched-pairs rank sum test. Panel A shows longitudinal samples from MS patients treated with
natalizumab who did not have PML, and Panel B shows samples from 4 individuals with natalizumab-associated PML.
doi:10.1371/journal.ppat.1003014.g003
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proteome longitudinally in subjects with MS who were initiating
therapy with natalizumab and in subjects who had natalizumab-
associated PML. The principal findings were: 1) T cell responses
were identified against all JC virus proteins and could be measured
ex vivo in the peripheral blood of individuals treated with
natalizumab and healthy subjects; 2) the magnitude and quality
of T cell responses to JCV and CMV did not change from baseline
through the first several months of natalizumab treatment; 3) the
frequency of T cells producing the cytokine IL-10 in response to
mitogenic stimulation temporarily increased after the first dose of
natalizumab; 4) individuals with PML either made no detectable T
cell responses to JCV or had JCV-specific CD4 T cell responses
uniquely dominated by IL-10 production rather than IFNc; and 5)
individuals shortly after PML diagnosis had higher levels of IL-10,
IL-5 and IL-15 in the CSF.
Whether JCV-specific T cell responses can be reliably measured
ex vivo [30,31] and the effect of natalizumab on these responses
[23,24] have both been the subject of some debate. Using ex vivo
stimulation with overlapping peptides, we readily detected CD4
and CD8 T cell responses to JCV by multiparameter ICS in
healthy subjects, subjects with MS and in some subjects with PML.
This approach could be useful in monitoring JCV-specific T cell
function in natalizumab-treated individuals in the context of a
vaccine or a risk stratification protocol. Our findings that JCV-
specific T cells are directed against each of the viral proteins and
that the specificity and immunodominance of the response varies
among individuals strongly suggest that measuring responses to all
viral proteins rather than VP1 alone is essential to obtaining a
complete picture of JCV-specific immunity. Our results also
suggest that measuring multiple cytokines rather than IFNc alone
allows for the identification of associations that would otherwise be
missed, and in particular highlight the potential importance of IL-
10 in evaluating T cell responses to JCV. In our longitudinal study
we found no difference in either the magnitude or functional
profile of the total JCV-specific T cell response during short-term
natalizumab treatment. Although the sample size of our study was
limited in power to detect longitudinal differences, the fact that no
difference was observed in any of the cytokines measured, or in
their relative contribution to the response at different time points,
suggests that JCV-specific T cell responses are not altered simply
by the initiation of natalizumab.
However, in the subjects with PML, JCV-specific CD4 T cell
responses were either undetectable or uniquely dominated by IL-
10. Importantly, it has been shown that IL-10 is detrimental to the
clearance of lymphocytic choriomeningitis virus (LCMV) infection
because of its inhibitory effect on virus-specific memory CD4 T
cells [25,26]. Furthermore, vaccines which stimulate CD4 T cell
IL-10 production can limit the elicitation of protective polyfunc-
tional CD4 T cells [32]. Thus, the production of IL-10 but not
IFNc, TNF or IL-2 by JCV-specific CD4 T cells may interfere
Figure 4. JCV-specific T cell responses in subjects with PML. Panel A shows the total response to JCV. For each of 4 subjects with PML, the
summed frequency of memory CD4 (left) and CD8 (right) T cells producing IFNc, TNF, IL-2 or IL-10 (indicated by colors) in response to all JCV peptides
is shown. Red bars indicate frequency of cells producing IFNc, including those that produce any combination of IL-2 and TNF in addition to IFNc. The
responses for subjects PML-1 and PML-2 are not significantly above background in these samples. Panel B shows the JCV-specific IL-10 response in
subjects PML-3 and PML-4. Subjects PML-1, 2, 3 and 4 were sampled 2 weeks, 2 months, 4 months and 5 years, respectively, after diagnosis with PML.
doi:10.1371/journal.ppat.1003014.g004
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Figure 5. CSF cytokine levels that vary between subjects with and without natalizumab-associated PML. Diagnostic CSF samples taken
from subjects with natalizumab-associated PML early in disease course were compared to samples from subjects who had suspected natalizumab-
associated PML but tested negative for JCV DNA. Panel A shows the proportion of CSF samples with detectable IL-10 in diagnostic samples from
subjects in whom natalizumab-associated PML was confirmed or ruled out, and the proportion of CSF samples in each group with IL-5 levels above
the lower limit of quantification (1.1 pg/mL). P values were calculated by Fisher’s exact test. Panel B shows IL-15 levels in the CSF samples.
Comparison of the non-PML and early time point PML samples was by Mann-Whitney test. For 8/10 subjects with PML, a later time point was
available. P values between paired longitudinal samples were calculated by Wilcoxon matched-pairs signed rank test.
doi:10.1371/journal.ppat.1003014.g005
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with antiviral activity to the detriment of control of JCV replication,
either locally in the CNS or in peripheral tissues, and may
consequently be causative of PML. Another interpretation is that
IL-10 production, which was not detected until.4 months after the
subjects had developed PML, is a later-stage response to the
inflammation often associated with PML (PML-IRIS). This sample
size does not allowus definitively to link the time since diagnosis to the
presence of an IL-10 response. However, our finding that IL-10 was
detectable in 50% of early CSF samples suggests that IL-10
productionmay occur early in natalizumab-associated PMLdisease.
Importantly, these two interpretations are not mutually exclusive.
Although the role of IL-10 in PML associated with other conditions
has not been thoroughly characterized, one study found increased
JCV-specific IL-10 production by total PBMC from HIV+ PML
cases, but not from non-HIV PML cases [18]. This result suggests
that IL-10 may be associated with PML resulting from causes other
than natalizumab therapy.
Notably, we found that the frequency of memory CD4 T cells
that produce IL-10 upon mitogenic stimulation is transiently
increased after the first dose of natalizumab. It is tempting,
therefore, to speculate that natalizumab may skew the CD4 T cell
response toward IL-10 production and away from production of
IFNc, TNF, and IL-2. This suggests a possible mechanism by
which natalizumab treatment could lead to PML, as 50% of the
subjects with natalizumab-associated PML that we studied
produced IL-10 in response to JCV, and the other 50% had no
measurable T cell response to the virus. There are a number of
mechanisms by which natalizumab treatment could potentially
skew the CD4 T cell response toward IL-10 production, including
increasing antigen load through mobilization of infected CD34+
cells [8], which may affect the cytokine profile [32], altering the
antigen-presenting cells (APCs) that interact with the T cells [25],
or altering T cell trafficking and thus with which APCs the T cells
interact [5–7]. There is also the possibility that a direct effect of
natalizumab on T cells could affect cytokine production, as may
occur with ribavirin treatment for hepatitis C virus [33].
The low probability that any of the natalizumab-treated MS
study subjects could go on to develop PML is consistent with the
lack of JCV-specific IL-10 production in those subjects who did
not have PML. Furthermore, in this study we were only able to
measure T cell responses in the peripheral blood and were not able
to sample the CNS of subjects without PML. A previous study
showed that after 12 months of natalizumab treatment, levels of
IL-10 mRNA were increased in bulk CSF cells, while remaining
unchanged in PBMC [19]. Although this finding may be due to
altered CSF cell subset composition after treatment rather than
upregulation of IL-10, it supports the hypothesis that natalizumab
may alter the cytokine milieu in the CNS. Indeed, we found
increased levels of IL-10 and IL-5 in CSF samples from individuals
with natalizumab-associated PML. Although these cytokines are
not typically associated with control of virus replication or with
each other, their aberrant production may be indicative of an
immune response that fails to control JCV replication at the site of
disease. The increased CSF IL-15 we observed early in PML
disease is consistent with inflammatory CNS disease [34–37] but is
unlikely to be due solely to MS disease-associated inflammation
[36–38] as the PML and non-PML groups both consisted of
individuals with MS who were treated with natalizumab and had
neurological symptoms consistent with PML. Thus far, it is not
possible to demonstrate a causative link between IL-10 production
and PML as the very low incidence of natalizumab-associated
PML makes a prospective study unlikely. However, we believe that
the potential mechanism suggested by these data should inform
future work.
Taken together, our data provide a framework for under-
standing immune control of JC viremia and the development of
PML and suggest avenues of investigation to allow the better
monitoring, treatment and prevention of PML in natalizumab-
treated people. First, our finding that subjects with PML lacked
JCV-specific T cell responses or produced IL-10 in response to
stimulation suggests that immune monitoring might identify
natalizumab-treated individuals who are at risk of developing
PML, by screening subjects prior to treatment or while on
treatment. None of the MS patients without PML or healthy
subjects included in our study showed an absent or IL-10
producing T cell response similar to that observed in the subjects
with PML, and this suggests that individuals with these phenotypes
are relatively rare and could be identified by immune monitoring
prior to treatment. The potential of such screening of JCV-specific
T cell responses to identify a small number of individuals at risk for
the development of PML could be complementary to stratification
strategies based on antibody levels that are currently being tested
to identify approximately 50% of treated individuals who are at
increased risk [2,39]. Second, the unique IL-10 response to JCV in
two PML cases and the increased levels of IL-10 in the CSF of
subjects with PML suggests that IL-10 or the IL-10 receptor may
be potential therapeutic targets in natalizumab-associated PML
[26]. Finally, the poor magnitude or quality of the memory T cell
response to JCV in subjects with PML suggests that a vaccine
which boosts JCV-specific T cells that produce IFNc, TNF and
IL-2 could play a role in the prevention of natalizumab-associated
PML.
Materials and Methods
Ethics statement
The study was approved by the IRB of the University of Texas
Southwestern Medical Center. Written informed consent was
obtained from all study subjects.
Study subjects. Eight individuals were recruited who were
initiating natalizumab therapy (Tysabri, Biogen Idec) at the
University of Texas Southwestern Medical Center Multiple
Sclerosis Clinic. Subjects underwent a washout period of at least
two weeks and had blood samples taken immediately before the
first dose and each subsequent monthly infusion. Ten healthy
blood donors were recruited at the NIH Vaccine Research Clinic.
Blood samples from 4 subjects with natalizumab-associated PML
were obtained, and CSF samples from these individuals and 6
others, as well as 10 control subjects who had suspected PML but a
negative test for JCV were supplied by the NIH Laboratory of
Molecular Medicine and Neuroscience clinical testing lab. Tables
S1, S2, S3 describe certain clinical and laboratory characteristics
of all the included natalizumab-treated patients.
Cell isolation
Peripheral blood mononuclear cells (PBMC) were isolated from
whole blood by ficoll-hypaque density centrigugation (GE
Heathcare Life Sciences). PBMC were cryopreserved in freezing
media containing 90% fetal bovine serum and 10% DMSO for
use in T cell assays.
Cell stimulation
Frozen PBMC were thawed and washed twice with RPMI 1640
supplemented with 10% heat inactivated fetal calf serum, 100 U/
ml penicillin G, 100 U/ml streptomycin sulfate, and 1.7 mm
sodium glutamine (R-10) containing 10 U/ml DNase I (Roche
Diagnostics). Cells were then rested for two hours before being
washed and then plated in 96-well plates in 200 uL final volume of
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R10 with DNase I. All experiments were done at 56106 PBMC/
ml in the presence of 1 mg/ml each of aCD28 and aCD49d (BD
Bioscience), in the absence or presence of peptide antigens or SEB.
Cells were stimulated for 6 hours, with 10 mg/ml brefeldin A
(BFA) (Sigma Chemical Company) added after 1 hour. For
subjects PML-1, PML-2 and PML-3, freshly isolated PBMC were
stimulated for 16 hours with BFA added after 1 hour. For subject
PML-4 frozen PBMC were stimulated for 6 hours as described in
parallel with MS and healthy subjects.
Antibodies
Directly conjugated monoclonal antibodies (mAbs) specific for
the molecules listed were obtained from the following: CD3 APC-
H7, TNF Cy7PE, IFNc V450, IL-10 APC, IL-10 PE, IL-2 FITC,
CD3 Alexa700, IFNc FITC, IL-2 APC from BD Biosciences;
CD45RO-TRPE, CD27-Cy5PE from Beckman Coulter; CD4-
Cy55PE from Caltag, CD8 QD705 from Invitrogen, and IL-2
Alexa700 from BioLegend. The following antibodies were
conjugated in our laboratory according to standard protocols (http://
drmr.com/abcon/index.html): CD57-QD585, CD14-QD605, CD14
PacificBlue and CD19-QD655.
Immunofluorescence staining
Stimulated PBMC used for intracellular cytokine staining were
washed and pre-stained for 10 minutes with a pre-titered amount
of LIVE/DEAD fixable aqua dead cell stain (Molecular Probes).
Cells were then surface stained with a mixture of pre-titered
amounts of directly conjugated antibodies to CD27, CD45RO,
CD57, CD4, CD8, CD19, and CD14 made to a total volume
100 ml with Delbecco’s phosphate buffered saline (PBS). Cells were
stained for 30 min at 4uC in the dark. Cells were then washed and
permeabilized using the cytofix/cytoperm kit (BD Biosciences)
according to the manufacturer’s instructions. After intracellular
staining for CD3, IFNc, TNF, IL-2 and IL-10 cells were washed
one final time and fixed in PBS containing 1% paraformaldehyde
and then stored at 4uC. Flow cytometric analysis was done within
24 h of staining.
Flow cytometric analysis
Cells were analyzed with a modified LSRII (BD Immunocyto-
metry Systems) equipped for the detection of 18 fluorescence
parameters. Between 500,000 and 1,000,000 events were collected
for each sample. Electronic compensation was conducted with
antibody capture beads (BD Biosciences) stained separately with
individual mAbs used in test samples. All analytical gating was
performed using FlowJo version 9.0.1 (Tree Star, Inc. Ashland,
OR).
Gating
CD4 and CD8 memory T cells were identified by sequential
gating, using the same gating scheme for all analyzed samples.
Cells were identified as lymphocytes by Side Scatter Area (SSC-A)
and Forward Scatter Area (FSC-A), and as singlets by Forward
Scatter Area (FSC-A) and Forward Scatter Height (FSC-H).
Memory CD4 and CD8 cells were defined as Aqua LIVE/DEAD
stain2, CD142, CD192, CD3+, CD4+ and CD82 or CD8+ and
CD42, and memory cells were defined as CD45RO+ or
CD45RO2 and CD272. Cells positive for IFNc, TNF, IL-2 and
IL-10 were expressed as a percentage of either memory CD4 or
memory CD8 T cells. In all samples other than that from subject
PML-3, IL-10+ cells were defined as cells that were positive for
both anti-IL-10 PE and anti-IL-10 APC. In PML-3, IL-10+ cells
were defined by anti-IL-10 PE alone.
Peptide antigens
An amino acid sequence for the entire JCV coding region was
constructed based on Mad1 that also included any common
variants from NCBI and the literature [40], in order to cover the
vast majority of variation in the viral epitopes that are presented in
vivo in our patient population (particularly focusing on genotypes 1,
3, 4 and 6). 15mers overlapping by 11 amino acids were generated
from this sequence, to create 381 peptides, plus 162 additional
peptides containing variant amino acids, for a total of 543
peptides. These were dissolved in DMSO and pooled to create 5
peptide pools: the VP1, large T antigen and agnoprotein pools
contained the entire sequence of these proteins, while the VP2
pool contained only peptides that were not shared with VP1, and
the small t antigen pool contained peptides not shared with large T
plus 5 additional peptides that cover the T9 splice variants [41].
The number of peptides in each pool was Agnoprotein – 27, VP1
– 149, VP2 – 109, large T – 222, small t – 36. Because the peptide
stimulations were done in pools rather than individually, and
contained multiple variants of the same peptide, it is theoretically
possible that competition amongst peptides in the same pool for
the same MHC protein decreased sensitivity of the assay to detect
a response. Because we use high concentrations of each peptide
(2 mg/ml each), this should only occur if a pool contains a peptide
with at least 100-fold higher affinity for MHC than typical
peptides, and thus should be a very rare event. Limitations on the
number of cells available from samples prevents the assessment of
all peptides individually and necessitates the commonly-used
pooling approach. Peptides were obtained from New England
Peptide, and were.70% pure. For measurement of CMV-specific
T cells, 138 15mers overlapping by 11 amino acids corresponding
to the entire CMV pp65 protein sequence were pooled and
dissolved in DMSO. CMV pp65 peptides were obtained from JPT
peptide technology, and were .70% pure. In pooled peptide
mixes, each peptide was at a concentration of 400 mg/ml. Five ml
were added for each ml of assay volume. Final concentration of
peptides was 2 mg/ml.
Plasma and CSF cytokines. Cytokines were measured using
the Bio-Plex Pro Human Cytokine 27-plex Assay according to
manufacturer’s instructions (Bio-Rad Laboratories, Hercules, CA).
CSF samples were assayed at a dilution of 1:2 due to sample
volume limitations.
Statistical analysis
Statistical comparisons were performed using Prism (GraphPad
Software, San Diego, CA). Experimental variables were analyzed
using Fisher’s Exact test, Mann-Whitney U test or Wilcoxon
matched-pairs signed rank test. Bars depict median values. P-
values ,0.05 were considered significant. Analysis and graphical
representation of cytokine production was conducted by using the
data analysis program Simplified Presentation of Incredibly
Complex Evaluations (SPICE version 5.05013 Beta) [28].
Supporting Information
Figure S1 JCV-specific memory T cell responses in
healthy subjects. CD4 (top) and CD8 (bottom) memory T cell
responses from all ten healthy subjects are shown, with the
background-subtracted magnitude of the response to each JCV
protein depicted by colored bars. Responses were measured by
production of any combination of IFNc, TNF and IL-2. The
finding that all non-PML subjects had T cells that responded to
JCV peptide pools does not necessarily indicate they were infected
with JCV. It is possible that such responses may be specific for BK
virus, as it shares significant homology with JCV. As negative
JCV T Cell Responses during Natalizumab Treatment
PLOS Pathogens | www.plospathogens.org 9 November 2012 | Volume 8 | Issue 11 | e1003014
serology does not definitively rule out latent JCV infection one
cannot fully distinguish JCV-infected from uninfected subjects
cross-sectionally. However, the presence of T cells that respond to
JCV, whether or not these cells were originally primed to JCV
itself, has implications for the control of new infection or
reactivation of latent JCV.
(PDF)
Figure S2 JCV-specific IL-10 response in subject PML-4.
PBMC were stimulated for 6 hours with costimulatory molecules
alone (left) or with the addition of VP1 peptides (right). Plots show
memory CD4 T cells. The X-axis shows fluorescence intensity for
IL-10 PE, and the Y-axis shows fluorescence intensity for IL-10
APC. The diagonal population are IL-10+ cells.
(PDF)
Table S1 Characteristics of longitudinal subjects initi-
ating therapy with Natalizumab. Characteristics of subjects
with MS initiating therapy with natalizumab are shown, including
subject number, age, gender, diagnosis and estimated Expanded
Disability Status Scale (EDSS).
(DOCX)
Table S2 Characteristics of subjects with Natalizumab-
associated PML analyzed for T cell responses. For the
subjects with natalizumab-associated PML included in the T cell
response analysis, the CSF viremia at time of diagnosis is listed,
along with the plasma viremia at the time of sampling, the number
of doses of natalizumab that the subject received, and the length of
time from diagnosis to sampling for the T cell assays.
(DOCX)
Table S3 Characteristics of subjects with Natalizumab-
associated PML who were analyzed for CSF cytokine
levels. For the subjects with natalizumab-associated PML
included in the CSF cytokine analysis, the CSF viral load at
diagnosis (timepoint 1) and at a later timepoint (timepoint 2) are
shown, with the length of time between the diagnostic sample
(timepoint 1) and the later sample (timepoint 2).
(DOCX)
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